Abstract-We have shown previously that inhibition of small conductance Ca 2ϩ -activated K ϩ (SK) channels is antiarrhythmic in models of acutely induced atrial fibrillation (AF). These models, however, do not take into account that AF derives from a wide range of predisposing factors, the most prevalent being hypertension. In this study we assessed the effects of two different SK channel inhibitors, NS8593 and UCL1684, in aging, spontaneously hypertensive rats to examine their antiarrhythmic properties in a setting of hypertension-induced atrial remodeling. Male spontaneously hypertensive rats and the normotensive Wistar-Kyoto rat strain were divided in 2ϫ3 groups of animals aged 3, 8, and 11 months, respectively. The animals were randomly assigned to treatment with NS8593, UCL1684, or vehicle, and open chest in vivo experiments including burst pacing-induced AF were performed. The aging spontaneously hypertensive rats were more vulnerable to AF induction both by S2 stimulation and burst pacing. Vehicle affected neither the atrial effective refractory period nor AF duration. SK channel inhibition with NS8593 and UCL1684 significantly increased the atrial effective refractory period and decreased AF duration in both the normotensive and hypertensive strains with no decline in efficacy as age increased. In conclusion, SK channel inhibition with NS8593 and UCL1684 possesses antiarrhythmic properties in a rat in vivo model of paroxysmal AF with hypertension-induced atrial remodeling. The present results support the notion that SK channels may offer a promising new therapeutic target in the treatment of AF. 
A trial fibrillation (AF) is the most common cardiac arrhythmia encountered in the clinic and contributes significantly to cardiac morbidity and mortality. There is a two-fold increase in the risk of death in patients with a history of AF, and the risk of embolic stroke is increased 4-to 5-fold. 1, 2 The use of conventional antiarrhythmic compounds has been limited by potentially fatal ventricular arrhythmias. Existing antiarrhythmic drugs approved for the treatment of AF exhibit moderate efficacy for AF termination and suppression and have significant associated adverse effects, resulting in poor patient tolerance. Ongoing drug development has focused on increasing safety by developing atrialspecific agents. Atrial selectivity can be achieved by targeting ion channels that are selectively expressed in the atria or by blocking Na ϩ channels in a state-dependent manner that favors blocking of atrial rather than ventricular action potentials. However, the number of such atrial-specific ion channels is limited. So far the ion channels responsible for the acetylcholine-activated current and the ultra rapid delayed rectifier potassium current have been the main targets in the search for an atrial-specific antiarrhythmic drug, but until now, no compound has been shown to exhibit exclusive selectivity for any of these currents. 3 Within the last few years, the existence of cardiac small conductance Ca 2ϩ -activated K ϩ (SK) channels has been documented, and their functional role is gradually being elucidated. 4 -12 Three subtypes of SK channels (SK1-3) mediating a Ca 2ϩ -activated K ϩ current (I KCa ) exist, and biochemical evidence indicates that SK2 channels are predominantly expressed in the atria of human and mouse hearts as compared with the ventricles. Also, SK1 channels have been reported to be predominantly expressed in the atria of mouse hearts. SK3 channels, however, show similar levels of expression in atria and ventricles. 4, 5 Ellinor et al 13 reported a multicenter trial, which established relationship between lone AF and common variants in the gene KCNN3, which codes for the SK3 channel.
The increasing evidence for atrial selectivity of SK1 and SK2 isoforms raises the possibility that drugs modulating these channels may target cardiac disease in an atrial selective manner, thereby decreasing the risk of ventricular proarrhythmic effects. The precise role of SK channels in the heart still remains unanswered, but they have been suggested to play an important role in atrial repolarization and fibrillation, making them an interesting atrial-specific target in the treatment of AF. 7, 8 We have shown previously that inhibition of SK channels is antiarrhythmic in models of acutely induced AF. 9 These models, however, do not take into account that AF derives from a wide range of predisposing factors, the most prevalent being hypertension. 1, 14, 15 AF is secondary to underlying heart disease in 70% of patients, whereas lone AF patients with no detectable etiology constitute the remaining 30%. 16 The spontaneously hypertensive rat (SHR) is a model of systemic hypertension that exhibits a progression of hypertension and left ventricular hypertrophy from a stable form with normal cardiac function. SHRs have been used extensively in combination with the normotensive Wistar-Kyoto rat (WKY), which were inbred as a normotensive control strain from the SHR, to study cardiac adaptation to increased afterload. [17] [18] [19] [20] [21] [22] [23] The SHR shows a hypertension-induced remodeling of the left atrium involving atrial enlargement, interstitial fibrosis, and cellular electric remodeling, which, in the aging SHR, leads to increased vulnerability to burst pacing-induced atrial arrhythmias. 18, 24 Interstitial fibrosis can increase electrophysiological heterogeneity and slow conduction velocity by creating minuscule zigzagging circuits, thereby creating a substrate for multiple reentry. 14, 25 In this study we assessed the effects of two different SK channel inhibitors, NS8593 and UCL1684, in aging, hypertensive rats to examine their antiarrhythmic potential in a setting of hypertension-induced atrial remodeling. 
Materials and Methods

All
Animals and Experimental Design
Male SHRs and WKYs (SHR/NHsd and WKY/NHs, respectively) aged 10 weeks were acquired from Harlan Laboratories in two batches with equal numbers of SHRs and WKYs, which were kept in in-house storage facilities. Each batch was divided into 2ϫ3 groups of animals, and experiments were conducted when the rats were aged 3, 8, and 11 months, respectively (termed SHR3, SHR8, SHR11, WKY3, WKY8, and WKY11). A total of 152 rats were used.
Before anesthetizing animals for the open chest in vivo experiments, noninvasive recordings of systolic blood pressure from all of the animals were obtained using the tail-cuff method without restraining the rats (ML125/R NIBP, ADInstruments). This also allowed for recordings of the heart rate at sinus rhythm (SR) from conscious animals.
Open chest in vivo experiments were conducted as described previously with a few modifications. 9 Monophasic action potential recordings were obtained with a monophasic action potential electrode placed on the right atrium. The atrial effective refractory period (aERP) and the Wenckebach cycle length (WCL), as well as pacing-induced AF duration, were measured before and after IV injections of NS8593 (5 mg/kg), UCL1684 (3 mg/kg), or vehicle. For further details on the in vivo experiments please see the online Data Supplement at http://hyper.ahajournals.org.
Data Analysis
Data analysis and drawings were performed using GraphPad Prism software (GraphPad Software, San Diego, CA), or Chart 7 software (ADInstruments). Data were normalized by dividing the values obtained after injection by the values obtained at baseline for each individual experiment. Continuous data are summarized using the mean and SEM or the median with the 25% to 75% quartiles in sharp brackets. Data were subject to Wilcoxon matched-pairs signed-rank test, Kruskal-Wallis test, 1-way ANOVA, or 2-way ANOVA as appropriate; details are provided in text or figure legends. When necessary, probability values were Bonferroni corrected for multiple comparisons and were considered significant when Ͻ0.05.
Drugs and Solutions
Unless otherwise mentioned, all of the chemicals used were of analytic grade and obtained from Sigma-Aldrich. NS8593 and UCL1684 were synthesized at NeuroSearch A/S (Ballerup, Denmark). Drugs were dissolved in the vehicle solution consisting of 5% Cremophor in glucose liquid for infusion of 50 mg/mL, which was produced by B. Braun Melsungen AG and obtained from a Danish pharmacy.
Results
Blood Pressure, Weight, and Hypertrophy
For background data such as systolic blood pressure, weight, heart weight, and SR, please see the online Data Supplement.
AF Inducibility and aERP at Baseline
The absolute values for aERP separated for strain and age are shown in Figure 1A . SHR3 and SHR11 have significantly shorter aERPs than the age-matched WKY, and the WKY8 has significantly shorter aERP than WKY3. There is no statistically significant change in aERP for the SHR over time, but a slight tendency toward a decreased aERP as age increases can be observed.
The primary method of inducing AF in this study was by burst pacing, but upon applying S2 stimulation to record aERP values, episodes of AF were seen in a number of rats ( Figure 1B and 1D ). SHRs aged 8 and 11 months had significantly longer episodes of AF than the age-matched WKY, and SHR11 had significantly longer AF episodes than the SHR3.
With burst pacing, AF could be induced in both strains at all of the ages, but the durations of the AF episodes were significantly longer in the oldest SHRs than in any other group ( Figure 1C and 1E ). This is consistent with previous reports of increased vulnerability to atrial tachyarrhythmias in the aging SHRs associated with markedly increased interstitial fibrosis in the left atrium. 24 
Effects of I KCa Inhibition on aERP and AF Duration
For several years, multiple-and single-circuit re-entry have been widely accepted as major mechanisms in the perpetuation of AF. According to these hypotheses, drugs that increase aERP should be able to interfere with AF by preventing perpetuation of wavelets. 26 -28 Consistent with this, we observed a correlation between the aERP and AF in our experiments, which is best described by an exponential function as depicted in Figure 2 . For AF durations and aERP values presented individually for each animal strain, age group, and treatment group please see Table S2 in the online Data Supplement.
We found that administration of 5 mg/kg of NS8593 increased the aERP from 34 ms [23- Figure 3B ). Thus, while vehicle affected neither aERP nor AF duration, the negative allosteric modulator of SK channels, NS8593, and the SK channel pore blocker, UCL1684, both significantly increased the aERP and decreased the AF duration in both the normotensive and hypertensive strains with no decline in efficacy as age increased (Figure 4) .
Effects of I KCa Inhibition on Pacemaking Tissues
In 2008, Zhang et al 11 examined the role of SK2 channels in pacemaking tissues in the heart. It was demonstrated that mice overexpressing the SK2 channel had shortened WCL and increased atrioventricular (AV)-node conduction when compared with wild-type mice. In the same study it was found that SK2 knockout mice had longer WCL and slower AV-node conduction than wild-type mice. Similar effects were seen in the sino-atrial node in which SK2 channel knockout led to sinus bradycardia, whereas overexpression led to shortening of the RR interval. 11 We, therefore, examined the effects of I KCa inhibition on SR and AV-node conduction by normalizing recordings of WCL and SR after drug administration to baseline values ( Figure 5 ). The SR was decreased by I KCa inhibition ( Figure  5A ). SR was decreased to 86.7Ϯ1.7% of baseline value by 3 mg/kg of UCL1684, whereas 5 mg/kg of NS8593 did not reach statistical significance by reducing SR to 93.1Ϯ1.4% when compared with control values of 96.5Ϯ1.0%. The same pattern was observed with regard to AV-nodal effects; the WCL was increased by I KCa inhibition ( Figure  5B ). Treatment with 3 mg/kg of UCL1684 increased WCL to 115.0Ϯ5.1% of baseline value, whereas 5 mg/kg of NS8593 did not reach statistical significance (104.6Ϯ2.1% of baseline) when compared with control (102.3Ϯ2.2% of baseline).
Discussion
We here provide evidence that the two different SK channel inhibitors, NS8593 and UCL1684, increase aERP and impede AF in a setting of hypertension-induced atrial remodeling in aging rats.
Selectivity data obtained on NS8593 show no effects of the compound on other cardiac-relevant ion channels than SK channels in concentrations Յ10 mol/L. 9, 29 Because the selectivity data include neuronal Na v 1.2, but not cardiac Na v 1.5, it cannot be ruled out that Na v 1.5 inhibition interferes with the recordings of AF durations in our experiments. However, two potent SK channel pore blockers, structurally unrelated to NS8593 and with a different mode of action than NS8593, exert antiarrhythmic effects comparable to those of NS8593, 9 and in combination with the selectivity data, this suggests that the antiarrhythmic effect of NS8593 is primarily a result of SK channel inhibition.
We have shown previously that these structurally and mechanistically different inhibitors of SK channels possess antiarrhythmic properties in models of acutely induced AF when no atrial remodeling has occurred. 9 However, hypertension is the most prominent predisposing factor for the clinically encountered AF. Thus, the aging SHR constitutes a relevant preclinical model for addressing the potential antiarrhythmic properties of potential AF drugs, because it incorporates hypertension-induced atrial remodeling with atrial enlargement, interstitial fibrosis, and cellular electric remodeling. 24 Theories of the mechanism of AF involve two main processes: one or more rapidly depolarizing foci that function as triggers of arrhythmia and a fibrillation-prone atrium allowing re-entry with one or more re-entrant circuits. Hypertension-induced atrial remodeling provides such a fibrillation-prone atrium. We demonstrate here the inhibition of I KCa diminishes the substrate for arrhythmia by increasing aERP, thereby markedly reducing AF in this model. This further strengthens our previous conclusion, that SK channels represent a promising new therapeutic target in the treatment of AF.
Effects of I KCa Inhibition on Pacemaking Tissues
In the present study, we also examined the effects of I KCa inhibition on SR and WCL and observed small but statistically significant effects on both parameters. The magnitude of the effects on pacemaking tissues was not equal for the two different SK channel inhibitors; the effects of UCL1684 were greater than the effects of NS8593, although the effects on aERP prolongation and AF reduction were comparable. The spontaneous depolarization of nodal tissue is controlled by influx of Ca 2ϩ via L-type Ca 2ϩ channels. A conjectural explanation for the difference in magnitude of effect could, therefore, be that an SK channel pore blocker such as UCL1684 would have more pronounced effects than a negative modulator such as NS8593 if the intracellular-free Ca 2ϩ concentration in pacemaking tissue is sufficiently great to overcome the negative modulation. However, because data on the free plasma concentrations of the compounds and data on intracellular Ca 2ϩ concentrations are not available, a direct comparison of the efficacy of these two compounds cannot be meaningfully made.
The SK channels in the AV-nodal tissue may play a role under certain pathological conditions; it may be speculated that, during AF, as in the rest of the atrial tissue, the rapid depolarization increases intracellular Ca 2ϩ and potentiates the I KCa and thereby the AV-nodal conduction. Inhibition of SK channels may, therefore, represent an attractive method of modulating ventricular rate during atrial tachyarrhythmias. The same could be argued for the sinus-nodal effects under a condition of sinus-nodal tachycardia. However, this will need to be addressed in future studies.
Conclusions
In this study it has been confirmed that two chemically and mechanistically different SK channel inhibitors possess antiarrhythmic properties in a rat in vivo model of paroxysmal AF with hypertension-induced atrial remodeling in aging rats. Hypertension-induced atrial remodeling in aging rats did not reduce the efficacy of I KCa inhibition, which prolonged the *** *** *** *** *** *** Figure 4 . Effects of Ca 2ϩ -activated K ϩ current (I KCa ) inhibition on atrial fibrillation (AF) duration in normotensive and hypertensive strains at different ages. A, Three 2-way ANOVAs of strain/I KCa inhibition effects on AF duration. In all three cases, the strain does not contribute to the variance (Ͻ0.1% in all cases, Pϭ0.84, Pϭ0.80, and Pϭ0.99 at ages 3, 8, and 11 months, respectively). I KCa inhibition is equally effective regardless of strain (Pϭ0.83, Pϭ0.88, and Pϭ0.95 at ages 3, 8, and 11 months, respectively). I KCa inhibition contributes significantly to the variance (PϽ0.0001 at all ages). B, Two 2-way ANOVAS of age/I KCa inhibition effects on AF duration. Age does not contribute to the variance (Ͻ0.1% in both cases, Pϭ0.97 and Pϭ0.98 for Wistar-Kyoto rat [WKY] and spontaneously hypertensive rat [SHR], respectively). The effect of I KCa inhibition does not change significantly with increasing age for any of the strains (3.4%, Pϭ0.31, and 1.7%, Pϭ0.78, of the total variance caused by interaction for WKY and SHR, respectively. Again, I KCa inhibition contributes significantly to the variance (PϽ0.0001 for both strains). A Bonferroni post hoc test testing differences between I KCa inhibitor and vehicle for each age group reveals that AF duration is significantly shortened both by NS8593 and UCL1684, which is indicated in the figure with ** and *** for PϽ0.01 and PϽ0.001, respectively. Values of PϽ0.05 are denoted by * vs age-matched WKY, and by † and ‡ vs corresponding 3-month-old and 8-month-old groups, respectively. In the same way, **, † †, and ‡ ‡ and ***, † † † and ‡ ‡ ‡ denote PϽ0.01 and PϽ0.001, respectively.
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Effects on AF in Aged SHRs by I KCa InhibitionaERP and thereby impeded AF, with equal efficacy in normotensive and hypertensive strains at all ages.
Perspectives
AF is the most common form of arrhythmia in humans, and current options for antiarrhythmic therapy of AF are limited by marginal efficacy and toxicity, including proarrhythmia, making new drug development crucial. We have demonstrated previously that inhibition of SK channels is effective in preventing and terminating AF in several animal species, providing the first experimental evidence that pharmacological targeting of SK channels may be a promising novel therapeutic approach for treatment of AF in humans. The present study demonstrates for the first time that SK channel inhibitors show efficacy in a hypertension-remodeled animal heart, which is characterized by a higher susceptibility to AF. Although further studies are warranted to address the clinical relevance of these findings, the present results support the notion that SK channels may offer a promising new therapeutic target in the treatment of AF. 
